Handelsavisen
prelaunch
Companies ›Healthcare ›XAIR
XA
XAIR — Nasdaq Medical Equipment & Supplies

Beyond Air, Inc.

$6,23
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
51,7M USD
P/E
—
EV / Rev
-1,1x
Div yield
—
Op margin
-378,2 %
ROE
-542,8 %
Net margin
-433,0 %
Debt / equity
—
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$0,43
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About

Beyond Air, Inc. is classified under Healthcare / Medical Equipment & Supplies and appears not currently profitable on the latest normalized snapshot.

Business. Beyond Air, Inc. (XAIR) is a medical devices company operating within the Healthcare Equipment & Supplies sector. The firm is headquartered in the United States and is primarily listed on the Nasdaq stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

Classification70 %
SectorHealthcare
Business sectorHealthcare Equipment & Supplies
Industry groupMedical Equipment, Supplies & Distribution
IndustryMedical Equipment & Supplies
ActivityMedical Devices
Generated · rules-based
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
  • EarningsQ2 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership→
Geode Capital Management, L.L.C.
largest disclosed fund holder
Profitability→
-542,8 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning XAIR.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to XAIR. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ2 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    Briefing · model-assisted

    Beyond Air Inc. (XAIR) has recorded its first notable institutional holder activity, marking a significant baseline event for the ticker. As of June 30, 2024, an investor identified by ID 466 added a position of 518,985 shares, valued at approximately $0.28 million. This acquisition represents a weight of roughly 0.0006% in the investor’s portfolio and was detected on June 28, 2026. This addition is particularly material because it constitutes the first analysis for this ticker, meaning there is no prior basis for computing delta changes in holder activity. The emergence of this new holder provides the initial data point for tracking institutional interest in Beyond Air, establishing a reference for future monitoring of capital flows. The significance of this change is underscored by the company’s current profile, which shows zero analyst coverage and no index memberships. With only six top holders recorded, the entry of a new institutional participant highlights a shift in the shareholder base for a company that previously lacked visible institutional engagement in this dataset. While the company maintains a lean structure with no reported officers in the current snapshot, the addition of this holder suggests growing visibility. Investors should monitor this position as a potential indicator of broader institutional interest, given that Beyond Air remains outside major indices and lacks analyst ratings.

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Beyond Air, Inc. (XAIR) is a medical devices company operating within the Healthcare Equipment & Supplies sector. The firm is headquartered in the United States and is primarily listed on the Nasdaq stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

    Classification70 %
    SectorHealthcare
    Business sectorHealthcare Equipment & Supplies
    Industry groupMedical Equipment, Supplies & Distribution
    IndustryMedical Equipment & Supplies
    ActivityMedical Devices
    AI synthesis
    GENERATED

    Beyond Air, Inc. (XAIR) is currently classified as Medical Devices within Medical Equipment & Supplies (Healthcare). Classification confidence: 0.70 (rule-based classification). Capital structure on the latest snapshot: total assets 35,385,000 USD, total equity 6,126,000, short-term debt 0, long-term debt 0. Net cash position is approximately 11,641,000 USD. Self-calculated market cap is 3,552,792 USD (market_price × shares_outstanding_diluted). Profitability profile: revenue 7,679,000, gross profit 252,000, operating income -29,044,000, net income -33,249,000. Return on equity ~-542.8%. Return on assets ~-94.0%. Operating-cash-flow to net-income ratio is 0.55. Risk profile from automated assessment: liquidity risk high, dilution risk medium. Flags: Filings reference going-concern or substantial-doubt language.; Source documents mention dilution or offering risk.. Recent news context: [TRIGGER] 8-K: 8-K (sec_8k_material) on XAIR — filing_type=8-K; max_severity=medium; ignored_items=['9.01']; material_items=['3.03', '5.03']; all_items_found=['3.03', '5.03', '9.01']; severity_per_code={'3.03': 'medium', '5.03': 'medium'}; contributing_watchers=sec_8k_material (source=sec_8k_material; url=0001493152-26-032621). Additional context: 8-K: filing_type=8-K; max_severity=medium; ignored_items=['9.01']; material_items=['3.03', '5.03']; all_items_found=['3.03', '5.03', '9.01']; severity_per_code={'3.03': 'medium', '5.03': 'medium'}; contributing_watchers=sec_8k_material.

    Beyond Air Inc. (XAIR) has recorded its first notable institutional holder activity, marking a significant baseline event for the ticker. As of June 30, 2024, an investor identified by ID 466 added a position of 518,985 shares, valued at approximately $0.28 million. This acquisition represents a weight of roughly 0.0006% in the investor’s portfolio and was detected on June 28, 2026. This addition is particularly material because it constitutes the first analysis for this ticker, meaning there is no prior basis for computing delta changes in holder activity. The emergence of this new holder provides the initial data point for tracking institutional interest in Beyond Air, establishing a reference for future monitoring of capital flows. The significance of this change is underscored by the company’s current profile, which shows zero analyst coverage and no index memberships. With only six top holders recorded, the entry of a new institutional participant highlights a shift in the shareholder base for a company that previously lacked visible institutional engagement in this dataset. While the company maintains a lean structure with no reported officers in the current snapshot, the addition of this holder suggests growing visibility. Investors should monitor this position as a potential indicator of broader institutional interest, given that Beyond Air remains outside major indices and lacks analyst ratings.

    Key takeaways
    • Return on equity is about -542.8%.
    • Debt to equity is about 0.0x.
    • [TRIGGER] 8-K: 8-K (sec_8k_material) on XAIR — filing_type=8-K; max_severity=medium; ignored_items=['9.01']; material_items=['3.03', '5.03']; all_items_found=['3.03', '5.03', '9.01']; severity_per_code={'3.03': 'medium', '5.03': 'medium'}; contributing_watchers=sec_8k_material (source=sec_8k_material; url=0001493152-26-032621)
    • Companyfacts coverage was partial; recent filing facts backfilled general_and_administrative.
    • false FY 0001641631 http://fasb.org/us-gaap/2026#UsefulLifeTermOfLeaseMember 0001641631 2025-04-01 2026-03-31 0001641631 2025-09-30 0001641631 2026-06-23 0001641631 2026-03-31 0001641631 2025-03-31 0001641631 2024-04-01 2025-03-31 0001641631 us-gaap:CommonStockMember 2024-03-31 0001641631 us-gaap:TreasuryStockCommonMember 2024-03-31 0001641631 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001641631 us-gaap:RetainedEarningsMember 2024-03-31 0001641631 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001641631 us-gaap:NoncontrollingInterestMember 2024-03-31 0001641631 2024-03-31 0001641631 us-gaap:CommonStockMember 2025-03-31 0001641631 us-gaap:TreasuryStockCommonMember 2025-03-31 0001641631 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001641631 us-gaap:RetainedEarningsMember 2025-03-31 0001641631 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001641631 us-gaap:NoncontrollingInterestMember 2025-03-31 0001641631 us-gaap:CommonStockMember 2024-04-01 2025-03-31 0001641631 us-gaap:TreasuryStockCommonMember 2024-04-01 2025-03-31 0001641631 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2025-03-31 0001641631 us-gaap:RetainedEarningsMember 2024-04-01 2025-03-31 0001641631 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2025-03-31 0001641631 us-gaap:NoncontrollingInterestMember 2024-04-01 2025-03-31 0001641631 us-gaap:CommonStockMember 2025-04-01 2026-03-31 0001641631 us-gaap:TreasuryStockCommonMember 2025-04-01 2026-03-31 0001641631 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2026-03-31 0001641631 us-gaap:RetainedEarningsMember 2025-04-01 2026-03-31 0001641631 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-04-01 2026-03-31 0001641631 us-gaap:NoncontrollingInterestMember 2025-04-01 2026-03-31 0001641631 us-gaap:CommonStockMember 2026-03-31 0001641631 us-gaap:TreasuryStockCommonMember 2026-03-31 0001641631 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001641631 us-gaap:RetainedEarningsMember 2026-03-31 0001641631 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-03-31 0001641631 us-gaap:NoncontrollingInterestMember 2026-03-31 0001641631 XAIR:BeyondCancerLtdMember 2021-11-04 0001641631 XAIR:NeuroNosLtdMember 2025-03-24 0001641631 2025-07-14 2025-07-14 0001641631 XAIR:StreetervilleCapitalLLCMember 2026-01-01 2026-01-31 0001641631 XAIR:StreetervilleCapitalLLCMember 2026-01-31 0001641631 2025-11-04 2025-11-04 0001641631 country:US 2026-03-31 0001641631 country:AU 2026-03-31 0001641631 country:BM 2026-03-31 0001641631 country:IE 2026-03-31 0001641631 country:CY 2026-03-31 0001641631 2026-03-31 2026-03-31 0001641631 us-gaap:AustralianTaxationOfficeMember 2025-04-01 2026-03-31 0001641631 us-gaap:AustralianTaxationOfficeMember 2024-04-01 2025-03-31 0001641631 us-gaap:AccountsPayableMember us-gaap:CustomerConcentrationRiskMember XAIR:FirstThirdPartyVendorsMember 2025-04-01 2026-03-31 0001641631 us-gaap:AccountsPayableMember us-gaap:CustomerConcentrationRiskMember XAIR:SecondThirdPartyVendorsMember 2025-04-01 2026-03-31 0001641631 us-gaap:AccountsPayableMember us-gaap:CustomerConcentrationRiskMember XAIR:ThirdPartyVendorsMember 2024-04-01 2025-03-31 0001641631 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember XAIR:CustomersOneMember 2025-04-01 2026-03-31 0001641631 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember XAIR:CustomersTwoMember 2025-04-01 2026-03-31 0001641631 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember XAIR:CustomersOneMember 2024-04-01 2025-03-31 0001641631 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember XAIR:CustomersTwoMember 2024-04-01 2025-03-31 0001641631 XAIR:BeyondCancerLtdMember 2026-03-31 0001641631 XAIR:NeuroNosLtdMember 2026-03-31 0001641631 XAIR:MutualFundsMember 2026-03-31 0001641631 us-gaap:FairValueInputsLevel1Member XAIR:MutualFundsMember 2026-03-31 0001641631 us-gaap:FairValueInputsLevel2Member XAIR:MutualFundsMember 2026-03-31 0001641631 us-gaap:FairValueInputsLevel3Member XAIR:MutualFundsMember 2026-03-31 0001641631 us-gaap:FairValueInputsLevel1Member 2026-03-31 0001641631 us-gaap:FairValueInputsLevel2Member 2026-03-31 0001641631 us-gaap:FairValueInputsLevel3Member 2026-03-31 0001641631 us-gaap:WarrantMember 2026-03-31 0001641631 us-gaap:FairValueInputsLevel1Member us-gaap:WarrantMember 2026-03-31 0001641631 us-gaap:FairValueInputsLevel2Member us-gaap:WarrantMember 2026-03-31 0001641631 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2026-03-31 0001641631 XAIR:MutualFundsMember 2025-03-31 0001641631 us-gaap:FairValueInputsLevel1Member XAIR:MutualFundsMember 2025-03-31 0001641631 us-gaap:FairValueInputsLevel2Member XAIR:MutualFundsMember 2025-03-31 0001641631 us-gaap:FairValueInputsLevel3Member XAIR:MutualFundsMember 2025-03-31 0001641631 us-gaap:FairValueInputsLevel1Member 2025-03-31 0001641631 us-gaap:FairValueInputsLevel2Member 2025-03-31 0001641631 us-gaap:FairValueInputsLevel3Member 2025-03-31 0001641631 us-gaap:WarrantMember 2025-03-31 0001641631 us-gaap:FairValueInputsLevel1Member us-gaap:WarrantMember 2025-03-31 0001641631 us-gaap:FairValueInputsLevel2Member us-gaap:WarrantMember 2025-03-31 0001641631 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2025-03-31 0001641631 us-gaap:MutualFundMember us-gaap:ShortTermDebtMember 2026-03-31 0001641631 us-gaap:MutualFundMember us-gaap:ShortTermDebtMember 2025-04-01 2026-03-31 0001641631 us-gaap:ShortTermDebtMember 2026-03-31 0001641631 us-gaap:ShortTermDebtMember 2025-04-01 2026-03-31 0001641631 us-gaap:MutualFundMember us-gaap:ShortTermDebtMember 2025-03-31 0001641631 us-gaap:MutualFundMember us-gaap:ShortTermDebtMember 2024-04-01 2025-03-31 0001641631 us-gaap:ShortTermDebtMember 2025-03-31 0001641631 us-gaap:ShortTermDebtMember 2024-04-01 2025-03-31 0001641631 us-gaap:MeasurementInputExpectedTermMember 2026-03-31 0001641631 us-gaap:MeasurementInputPriceVolatilityMember 2026-03-31 0001641631 us-gaap:MeasurementInputRiskFreeInterestRateMember 2026-03-31 0001641631 us-gaap:MeasurementInputExpectedTermMember 2025-03-31 0001641631 us-gaap:MeasurementInputPriceVolatilityMember 2025-03-31 0001641631 us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-03-31 0001641631 us-gaap:MeasurementInputSharePriceMember 2025-11-04 0001641631 us-gaap:MeasurementInputOptionVolatilityMember 2025-11-04 0001641631 us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-11-04 0001641631 us-gaap:WarrantMember 2024-03-31 0001641631 us-gaap:DerivativeMember 2024-03-31 0001641631 us-gaap:WarrantMember 2024-04-01 2025-03-31 0001641631 us-gaap:DerivativeMember 2024-04-01 2025-03-31 0001641631 us-gaap:DerivativeMember 2025-03-31 0001641631 us-gaap:WarrantMember 2025-04-01 2026-03-31 0001641631 us-gaap:DerivativeMember 2025-04-01 2026-03-31 0001641631 us-gaap:DerivativeMember 2026-03-31 0001641631 us-gaap:MutualFundMember 2026-03-31 0001641631 us-gaap:MutualFundMember 2025-03-31 0001641631 us-gaap:ComputerEquipmentMember 2026-03-31 0001641631 us-gaap:FurnitureAndFixturesMember 2026-03-31 0001641631 XAIR:ClinicalAndMedicalEquipmentMember srt:MinimumMember 2026-03-31 0001641631 XAIR:ClinicalAndMedicalEquipmentMember srt:MaximumMember 2026-03-31 0001641631 XAIR:EquipmentDeployableAsPartOfServiceOfferingMember 2026-03-31 0001641631 us-gaap:LeaseholdImprovementsMember 2026-03-31 0001641631 XAIR:ClinicalAndMedicalEquipmentMember 2026-03-31 0001641631 XAIR:ClinicalAndMedicalEquipmentMember 2025-03-31 0001641631 XAIR:EquipmentDeployableAsPartOfServiceOfferingMember 2025-03-31 0001641631 us-gaap:ComputerEquipmentMember 2025-03-31 0001641631 us-gaap:FurnitureAndFixturesMember 2025-03-31 0001641631 us-gaap:LeaseholdImprovementsMember 2025-03-31 0001641631 XAIR:TwoThousandAndTwentyFiveATMMember 2025-02-10 2025-02-10 0001641631 srt:MaximumMember 2025-02-10 0001641631 XAIR:TwoThousandAndTwentyFiveATMMember 2025-04-01 2026-03-31 0001641631 XAIR:TwoThousandAndTwentyFiveATMMember us-gaap:CommonStockMember 2024-04-01 2025-03-31 0001641631 XAIR:PurchaseAgreementMember 2025-11-04 2025-11-04 0001641631 XAIR:PurchaseAgreementMember 2026-01-01 2026-01-31 0001641631 XAIR:PurchaseAgreementMember 2026-01-31 0001641631 XAIR:PurchaseAgreementMember 2025-11-04 0001641631 us-gaap:CommonStockMember 2026-01-14 2026-01-14 0001641631 XAIR:TwoThousandTwentySixPreFundedWarrantsMember 2026-01-14 0001641631 XAIR:TwoThousandTwentySixCommonWarrantsMember 2026-01-14 0001641631 us-gaap:CommonStockMember 2026-01-14 0001641631 XAIR:PreFundedWarrantsMember 2026-01-14 2026-01-14 0001641631 XAIR:TwoThousandTwentySixPreFundedWarrantsMember 2026-01-16 2026-01-16 0001641631 XAIR:TwoThousandTwentySixPreFundedWarrantsMember 2026-01-14 2026-01-14 0001641631 us-gaap:PrivatePlacementMember 2025-04-01 2026-03-31 0001641631 us-gaap:PrivatePlacementMember 2026-03-31 0001641631 XAIR:TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember 2025-11-25 0001641631 XAIR:TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember 2025-03-31 0001641631 us-gaap:RestrictedStockUnitsRSUMember 2025-04-01 2026-03-31 0001641631 XAIR:TwoThousandThirteenBAPlanMember 2025-04-01 2026-03-31 0001641631 us-gaap:RestrictedStockUnitsRSUMember XAIR:TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember 2025-04-01 2026-03-31 0001641631 XAIR:TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember 2025-04-01 2026-03-31 0001641631 XAIR:TwoThousandThirteenEquityIncentivePlanMember 2026-03-31 0001641631 XAIR:TwoThousandThirteenEquityIncentivePlanMember 2025-04-01 2026-03-31 0001641631 XAIR:TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember 2024-04-01 2025-03-31 0001641631 2026-03-27 2026-03-27 0001641631 us-gaap:EmployeeStockOptionMember 2025-11-04 0001641631 us-gaap:EmployeeStockOptionMember srt:MinimumMember 2025-11-04 2025-11-04 0001641631 us-gaap:EmployeeStockOptionMember 2025-04-01 2026-03-31 0001641631 us-gaap:EmployeeStockOptionMember 2025-04-01 2025-12-31 0001641631 XAIR:TwoThousandTwentyFiveOptionRepricingMember 2024-11-22 2024-11-22 0001641631 XAIR:TwoThousandTwentyFiveOptionRepricingMember 2025-04-01 2026-03-31 0001641631 XAIR:TwoThousandTwentyFiveOptionRepricingMember 2024-04-01 2025-03-31 0001641631 XAIR:TwoThousandTwentyFiveOptionRepricingMember 2026-03-31 0001641631 XAIR:TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember 2025-04-01 2026-03-31 0001641631 XAIR:TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember 2022-11-03 2022-11-03 0001641631 XAIR:TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember 2022-11-03 0001641631 XAIR:TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember 2026-03-31 0001641631 XAIR:TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember 2025-03-31 0001641631 XAIR:TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember 2026-03-31 0001641631 XAIR:TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember 2024-04-01 2025-03-31 0001641631 XAIR:TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember 2025-04-01 2026-03-31 0001641631 us-gaap:CommonStockMember XAIR:BeyondCancerLtdMember srt:MinimumMember 2025-03-31 0001641631 us-gaap:CommonStockMember XAIR:BeyondCancerLtdMember srt:MinimumMember 2026-03-31 0001641631 us-gaap:WarrantMember 2025-09-08 0001641631 us-gaap:WarrantMember 2025-09-08 2025-09-08 0001641631 us-gaap:CommonStockMember XAIR:AmendedLoanAgreementMember 2025-11-03 0001641631 us-gaap:CommonStockMember 2026-01-16 0001641631 XAIR:TwoThousandTwentySixPreFundedWarrantsMember 2026-01-16 0001641631 XAIR:TwoThousandTwentySixPreFundedWarrantsMember 2025-01-16 2025-01-16 0001641631 XAIR:TwoThousandTwentyOneEmployeeStockPurchasePlanMember 2025-04-01 2026-03-31 0001641631 XAIR:TwoThousandTwentyOneEmployeeStockPurchasePlanMember 2024-04-01 2025-03-31 0001641631 us-gaap:RestrictedStockMember 2024-03-31 0001641631 us-gaap:RestrictedStockMember 2024-04-01 2025-03-31 0001641631 us-gaap:RestrictedStockMember 2025-03-31 0001641631 us-gaap:RestrictedStockMember 2025-04-01 2026-03-31 0001641631 us-gaap:RestrictedStockMember 2026-03-31 0001641631 XAIR:TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember 2024-03-31 0001641631 XAIR:TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember 2023-04-01 2024-03-31 0001641631 XAIR:TwoThousandAndThirteenBeyondAirEquityIncentivePlanMember 2026-03-31 0001641631 XAIR:TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember 2024-03-31 0001641631 XAIR:TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember 2023-04-01 2024-03-31 0001641631 XAIR:TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember 2024-04-01 2025-03-31 0001641631 XAIR:TwoThousandTwentyOneBeyondCancerLtdEquityIncentivePlanMember 2025-03-31 0001641631 XAIR:TwoThousandTwentyThreeNeuroNosLtdEquityIncentivePlanMember 2024-03-31 0001641631 srt:MinimumMember 2025-04-01 2026-03-31 0001641631 srt:MaximumMember 2025-04-01 2026-03-31 0001641631 srt:MinimumMember 2024-04-01 2025-03-31 0001641631 srt:MaximumMember 2024-04-01 2025-03-31 0001641631 XAIR:BeyondAirIncMember srt:MinimumMember 2025-04-01 2026-03-31 0001641631 XAIR:BeyondAirIncMember srt:MaximumMember 2025-04-01 2026-03-31 0001641631 XAIR:BeyondAirIncMember srt:MinimumMember 2024-04-01 2025-03-31 0001641631 XAIR:BeyondAirIncMember srt:MaximumMember 2024-04-01 2025-03-31 0001641631 XAIR:NeuroNosLtdMember 2025-04-01 2026-03-31 0001641631 XAIR:NeuroNosLtdMember 2024-04-01 2025-03-31 0001641631 us-gaap:ResearchAndDevelopmentExpense 2025-04-01 2026-03-31 0001641631 us-gaap:ResearchAndDevelopmentExpense 2024-04-01 2025-03-31 0001641631 us-gaap:GeneralAndAdministrativeExpense 2025-04-01 2026-03-31 0001641631 us-gaap:GeneralAndAdministrativeExpense 2024-04-01 2025-03-31 0001641631 XAIR:NitricGenAgreementMember 2026-03-31 0001641631 XAIR:NitricGenAgreementMember 2025-04-01 2026-03-31 0001641631 XAIR:AvenueAgreementMember 2026-03-31 0001641631 XAIR:AvenueAgreementMember 2025-04-01 2026-03-31 0001641631 XAIR:MarchTwoThousandTwentyFourRaiseMember 2026-03-31 0001641631 XAIR:MarchTwoThousandTwentyFourRaiseMember 2025-04-01 2026-03-31 0001641631 XAIR:AvenueExtensionAgreementMember 2026-03-31 0001641631 XAIR:AvenueExtensionAgreementMember 2025-04-01 2026-03-31 0001641631 XAIR:SeptemberTwoThousandTwentyFourEquityOfferingMember 2026-03-31 0001641631 XAIR:SeptemberTwoThousandTwentyFourEquityOfferingMember 2025-04-01 2026-03-31 0001641631 XAIR:SeptemberTwoThousandTwentyFourDebtInstrumentMember 2026-03-31 0001641631 XAIR:SeptemberTwoThousandTwentyFourDebtInstrumentMember 2025-04-01 2026-03-31 0001641631 XAIR:SeptemberTwoThousandTwentyFiveInducementMember 2026-03-31 0001641631 XAIR:SeptemberTwoThousandTwentyFiveInducementMember 2025-04-01 2026-03-31 0001641631 XAIR:JanuaryTwoThousandTwentySixEquityOfferingMember 2026-03-31 0001641631 XAIR:JanuaryTwoThousandTwentySixEquityOfferingMember 2025-04-01 2026-03-31 0001641631 XAIR:SubTotalMember 2026-03-31 0001641631 XAIR:PreFundedWarrantsSepTwoThousandTwentyFourMember 2026-03-31 0001641631 XAIR:PreFundedWarrantsSepTwoThousandTwentyFourMember 2025-04-01 2026-03-31 0001641631 XAIR:PreFundedWarrantsJanTwoThousandTwentySixMember 2026-03-31 0001641631 XAIR:PreFundedWarrantsJanTwoThousandTwentySixMember 2025-04-01 2026-03-31 0001641631 XAIR:SteveLisiMember 2026-03-31 0001641631 2026-03-01 2026-03-31 0001641631 2025-04-01 2025-04-30 0001641631 us-gaap:WarrantMember 2025-04-01 2026-03-31 0001641631 us-gaap:WarrantMember 2024-04-01 2025-03-31 0001641631 us-gaap:StockOptionMember 2025-04-01 2026-03-31 0001641631 us-gaap:StockOptionMember 2024-04-01 2025-03-31 0001641631 us-gaap:RestrictedStockMember 2025-04-01 2026-03-31 0001641631 us-gaap:RestrictedStockMember 2024-04-01 2025-03-31 0001641631 XAIR:PreFundedWarrantsMember 2025-04-01 2026-03-31 0001641631 XAIR:PreFundedWarrantsMember 2024-04-01 2025-03-31 0001641631 XAIR:LoanAgreementMember 2026-12-31 0001641631 XAIR:PromissoryNoteMember 2026-12-31 0001641631 2026-12-31 0001641631 XAIR:LoanAgreementMember 2026-03-31 0001641631 XAIR:LoanAndSecurityAgreementMember 2024-11-01 0001641631 XAIR:LoanAndSecurityAgreementMember 2025-11-02 0001641631 XAIR:LoanAndSecurityAgreementMember 2025-11-03 0001641631 srt:DirectorMember 2025-06-02 2025-06-02 0001641631 XAIR:AmendedLoanAgreementMember 2025-11-03 0001641631 XAIR:NotePurchaseAgreementMember 2025-11-04 0001641631 XAIR:NotePurchaseAgreementMember 2025-11-04 2025-11-04 0001641631 XAIR:StreetervilleCapitalLLCMember 2025-04-01 2026-03-31 0001641631 XAIR:StreetervilleCapitalLLCMember 2026-02-04 2026-02-04 0001641631 us-gaap:DomesticCountryMember 2025-03-31 0001641631 us-gaap:IsraelTaxAuthorityMember 2025-03-31 0001641631 us-gaap:RevenueCommissionersIrelandMember 2025-03-31 0001641631 XAIR:CypriotTaxMember 2025-03-31 0001641631 XAIR:NoExpirationMember 2025-03-31 0001641631 XAIR:NoExpirationMember 2024-04-01 2025-03-31 0001641631 us-gaap:StateAndLocalJurisdictionMember 2025-03-31 0001641631 us-gaap:StateAndLocalJurisdictionMember 2024-04-01 2025-03-31 0001641631 us-gaap:ResearchMember 2025-03-31 0001641631 us-gaap:ResearchMember 2024-04-01 2025-03-31 0001641631 country:IE 2025-04-01 2026-03-31 0001641631 country:IL 2025-04-01 2026-03-31 0001641631 XAIR:OptionAgreementMember 2017-01-12 2017-01-13 0001641631 XAIR:NitricGenIncMember XAIR:NitricGenAgreementMember 2018-01-30 2018-01-31 0001641631 XAIR:NitricGenIncMember XAIR:NitricGenAgreementMember XAIR:NextMilestonesMember 2018-01-30 2018-01-31 0001641631 XAIR:NitricGenAgreementMember XAIR:AfterSixMonthsMember XAIR:NitricGenIncMember 2018-01-30 2018-01-31 0001641631 XAIR:NitricGenIncMember XAIR:NitricGenAgreementMember 2018-01-31 0001641631 XAIR:NitricGenAgreementMember 2024-04-01 2025-03-31 0001641631 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember XAIR:SupplierMember 2026-03-31 0001641631 XAIR:BeyondCancerLtdMember XAIR:CertainInvestorsMember 2021-11-04 0001641631 XAIR:BeyondCancerLtdMember 2021-11-02 2021-11-04 0001641631 XAIR:BeyondCancerLtdMember 2021-11-04 0001641631 XAIR:BeyondCancerLtdMember 2021-11-16 2021-11-18 0001641631 XAIR:BeyondCancerLtdMember XAIR:InvestorsMember 2021-11-04 0001641631 XAIR:BeyondCancerLtdMember us-gaap:RelatedPartyMember 2021-11-04 0001641631 XAIR:SubscriptionAgreementMember 2025-03-24 0001641631 XAIR:SubscriptionAgreementMember 2025-03-24 2025-03-24 0001641631 XAIR:SubscriptionAgreementMember 2024-04-01 2025-03-31 0001641631 XAIR:SubscriptionAgreementMember XAIR:NeuroNosLtdMember 2025-03-31 0001641631 XAIR:SubscriptionAgreementMember 2025-04-01 2026-03-31 0001641631 XAIR:SubscriptionAgreementMember 2026-03-31 0001641631 XAIR:SubscriptionAgreementMember XAIR:NeuroNosLtdMember 2026-03-31 0001641631 XAIR:SubscriptionAgreementMember XAIR:NeuroNosLtdMember 2026-03-21 0001641631 XAIR:VariableInterestEntitiesMember 2025-04-01 2026-03-31 0001641631 XAIR:BeyondAirMember XAIR:SegmentMember XAIR:VariableInterestEntitiesMember 2026-03-31 0001641631 XAIR:BeyondCancerLtdMember XAIR:SegmentMember XAIR:VariableInterestEntitiesMember 2026-03-31 0001641631 XAIR:NeuroNosLtdMember XAIR:SegmentMember XAIR:VariableInterestEntitiesMember 2026-03-31 0001641631 srt:ParentCompanyMember XAIR:SegmentMember XAIR:VariableInterestEntitiesMember 2026-03-31 0001641631 XAIR:BeyondAirMember XAIR:SegmentMember XAIR:VariableInterestEntitiesMember 2025-04-01 2026-03-31 0001641631 XAIR:BeyondCancerLtdMember XAIR:SegmentMember XAIR:VariableInterestEntitiesMember 2025-04-01 2026-03-31 0001641631 XAIR:NeuroNosLtdMember XAIR:SegmentMember XAIR:VariableInterestEntitiesMember 2025-04-01 2026-03-31 0001641631 srt:ParentCompanyMember XAIR:SegmentMember XAIR:VariableInterestEntitiesMember 2025-04-01 2026-03-31 0001641631 XAIR:BeyondAirMember XAIR:SegmentMember XAIR:VariableInterestEntitiesMember 2025-03-31 0001641631 XAIR:BeyondCancerLtdMember XAIR:SegmentMember XAIR:VariableInterestEntitiesMember 2025-03-31 0001641631 XAIR:NeuroNosLtdMember XAIR:SegmentMember XAIR:VariableInterestEntitiesMember 2025-03-31 0001641631 srt:ParentCompanyMember XAIR:SegmentMember XAIR:VariableInterestEntitiesMember 2025-03-31 0001641631 XAIR:BeyondAirMember XAIR:SegmentMember XAIR:VariableInterestEntitiesMember 2024-04-01 2025-03-31 0001641631 XAIR:BeyondCancerLtdMember XAIR:SegmentMember XAIR:VariableInterestEntitiesMember 2024-04-01 2025-03-31 0001641631 XAIR:NeuroNosLtdMember XAIR:SegmentMember XAIR:VariableInterestEntitiesMember 2024-04-01 2025-03-31 0001641631 srt:ParentCompanyMember XAIR:SegmentMember XAIR:VariableInterestEntitiesMember 2024-04-01 2025-03-31 0001641631 srt:MinimumMember 2026-03-31 0001641631 srt:MaximumMember 2026-03-31 0001641631 XAIR:LungFitPHMember 2025-04-01 2026-03-31 0001641631 XAIR:LungFitPHMember 2024-04-01 2025-03-31 0001641631 XAIR:LungFitPHMember 2026-03-31 0001641631 XAIR:LungFitPHMember 2025-03-31 0001641631 XAIR:LungFitPHMember 2026-03-31 0001641631 XAIR:LungFitPHMember 2025-04-01 2026-03-31 0001641631 XAIR:LungFitPHMember 2024-04-01 2025-03-31 0001641631 XAIR:LungFitRPHMember 2025-04-01 2026-03-31 0001641631 XAIR:LungFitRPHMember 2026-03-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure XAIR:Integer iso4217:AUD iso4217:EUR UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED MARCH 31 , 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38892 BEYOND AIR, INC.

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 5

    Revenue grew at a 78.8% compound annual growth rate from FY2024 to FY2026, indicating strong top-line expansion momentum.

    Operating losses narrowed significantly from $63 million in FY2024 to $29 million in FY2026, demonstrating improved operational efficiency.

    The company achieved positive gross profit of $252,000 in FY2026, marking a turnaround from negative gross margins in prior years.

    Free cash flow outflows decreased substantially from $61.8 million in FY2024 to $19.2 million in FY2026, reducing cash burn.

    A current ratio of 3.20 suggests strong short-term liquidity coverage relative to current liabilities as of March 2025.

    BEAR CASE · 5

    The company faces high liquidity risk and medium dilution risk, threatening capital stability and shareholder value preservation.

    Net margin of -4.33% ranks in the bottom quartile of the Medical Equipment & Supplies cohort, signaling poor profitability.

    Return on equity of -5.43% places the company in the bottom quartile of its peer group, indicating inefficient capital usage.

    Capex to revenue ratio of 13.35% is above the cohort median of 3.24%, implying heavy capital intensity requirements.

    Cash conversion of 0.55 is below the cohort median of 0.73, suggesting weaker ability to convert earnings into cash.

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2025-12-31
    Q3 2025 · Quarter highlights
    Open report →

    Revenue $5.8M; Operating income -$21.9M.

    Revenue$5.8M
    Operating income-$21.9M
    Net income-$23.0M
    Free cash flow-$13.7M
    EPS—
    Operating cash flow-$13.2M
    Financials
    Income statement
    Revenue$5.8M
    Gross profit$158.0k
    Operating income-$21.9M
    Net income-$23.0M
    Margins
    Gross margin2.7%
    Operating margin-379.0%
    Net margin-397.9%
    FCF margin-236.9%
    Balance sheet
    Total assets$36.8M
    Total liabilities$28.5M
    Total equity$8.1M
    Cash & equivalents$6.6M
    Long-term debt—
    Cash flow
    Operating cash flow-$13.2M
    CapEx$478.0k
    Free cash flow-$13.7M
    SBC$4.9M
    P&L flow · revenue → net income
    Revenue $5.8MOperating costs $27.6MTax $1.1MNet income $23.0M
    Highlights
    • ▍Revenue $5.8M
    • ▍Operating income -$21.9M
    • ▍Net margin -397.9%

    Valuation FY

    Market price
    $6,23
    Market cap
    $3.6M
    Enterprise valueⓘ
    -$8.1M
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    -1.1x
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    0.7x
    P / Tangible bookⓘ
    0.7x
    Tangible book
    $5.2M
    Net cashⓘ
    $11.6M
    Current ratioⓘ
    3.8
    Debt / equityⓘ
    —
    ROAⓘ
    -94.0%
    ROEⓘ
    -5.4%
    Cash conversionⓘ
    55.0%
    CapEx / revenueⓘ
    13.4%
    SBC / revenueⓘ
    68.8%
    Dilution ratioⓘ
    -29.6%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Corporate eventM&A horizon
    M&A probabilityconf 5 %
    Probability
    5 %
    Base rate
    3 %
    Band
    —
    180-day horizon · target 2027-01-23 · 1,8× base rate
    No acquirer candidates identified by the signal model.
    Probabilistic model output — not investment advice. · generated 2026-07-27

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskMedium
    Liquidity riskHigh
    Filing-based flags
    • Filings reference going-concern or substantial-doubt language.
    • Source documents mention dilution or offering risk.

    Benchmarks vs cohort

    Op Margin-378,2 %Below median
    Net Margin-433,0 %Below median
    ROE-542,8 %Bottom quartile
    Capex / Rev13,4 %Best in class
    D/E0,00Above median
    Cash Conv0,55Below median

    Corporate actions / M&A

    M&A probabilityconf —
    Probability
    5 %
    Base rate
    3 %
    Band
    Moderate
    180-day horizon · target 2027-01-23 · 1,8× base rate
    No acquirer candidates identified by the signal model.
    Corporate actionsNo corporate-action source connected yet — splits, dividends and buyback events are not tracked for this company. Honest-dim (no data fabricated).

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net acquired 664 695 sh48 grants9 insiders
    • Goodman Robert ScottDirector, Chief Executive Officer · Series A Warrants → Common StockAcquired 34 722 @ $5,51purchase · 2026-07-29
    • MOORHEAD DANIEL JChief Financial Officer · Series B Warrant → Common StockAcquired 4 340 @ $5,51purchase · 2026-07-29
    • Goodman Robert ScottDirector, Chief Executive Officer · Series B Warrants → Common StockAcquired 34 722 @ $5,51purchase · 2026-07-29
    • MOORHEAD DANIEL JChief Financial Officer · Series A Warrant → Common StockAcquired 4 340 @ $5,51purchase · 2026-07-29
    • MOORHEAD DANIEL JChief Financial Officer · Stock Option (right to buy) → Common StockAcquired 70 000 @ $0,79grant · 2026-01-05
    • Lisi Steven A.Director, CEO and Chairman of the Board · Stock Options (Right to buy) → Common StockAcquired 12 500 @ $1,95grant · 2025-11-04
    • Lee YooriDirector · Stock Options (Right to buy) → Common StockDisposed 2 000 @ $10,80disposition · 2025-11-04
    • Lee YooriDirector · Stock Options (Right to buy) → Common StockAcquired 2 000 @ $1,95grant · 2025-11-04
    • Lee YooriDirector · Stock Options (Right to buy) → Common StockDisposed 1 500 @ $10,80disposition · 2025-11-04
    • Lee YooriDirector · Stock Options (Right to buy) → Common StockAcquired 1 500 @ $1,95grant · 2025-11-04
    • Lee YooriDirector · Stock Options (Right to buy) → Common StockDisposed 1 250 @ $10,80disposition · 2025-11-04
    • Lee YooriDirector · Stock Options (Right to buy) → Common StockAcquired 1 250 @ $1,95grant · 2025-11-04
    • Lee YooriDirector · Stock Options (Right to buy) → Common StockDisposed 750 @ $10,80disposition · 2025-11-04
    • Lee YooriDirector · Stock Options (Right to buy) → Common StockAcquired 750 @ $1,95grant · 2025-11-04
    • Lee YooriDirector · Stock Options (Right to buy) → Common StockDisposed 3 750 @ $5,89disposition · 2025-11-04
    • Lee YooriDirector · Stock Options (Right to buy) → Common StockAcquired 3 750 @ $1,95grant · 2025-11-04
    • Larson Douglas QuintonChief Financial Officer · Stock Options (Right to buy) → Common StockAcquired 6 000 @ $1,95grant · 2025-11-04
    • Larson Douglas QuintonChief Financial Officer · Stock Options (Right to buy) → Common StockDisposed 1 000 @ $10,80disposition · 2025-11-04
    • Larson Douglas QuintonChief Financial Officer · Stock Options (Right to buy) → Common StockAcquired 1 000 @ $1,95grant · 2025-11-04
    • Larson Douglas QuintonChief Financial Officer · Stock Options (Right to buy) → Common StockDisposed 3 750 @ $10,80disposition · 2025-11-04
    • Larson Douglas QuintonChief Financial Officer · Stock Options (Right to buy) → Common StockAcquired 3 750 @ $1,95grant · 2025-11-04
    • Larson Douglas QuintonChief Financial Officer · Stock Options (Right to buy) → Common StockDisposed 17 500 @ $5,89disposition · 2025-11-04
    • Larson Douglas QuintonChief Financial Officer · Stock Options (Right to buy) → Common StockAcquired 17 500 @ $1,95grant · 2025-11-04
    • Goodman Robert ScottDirector · Stock Options (Right to buy) → Common StockDisposed 187 @ $10,80disposition · 2025-11-04
    • Goodman Robert ScottDirector · Stock Options (Right to buy) → Common StockAcquired 187 @ $1,95grant · 2025-11-04

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Regulatory filings
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    • Reference data
    How metrics are computed
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Ev To Revenue
      enterprise_value / revenue
    • Market Cap
      market_price * shares_outstanding_diluted
    • Return On Assets
      net_income / total_assets
    • Price To Tangible Book
      market_price / (tangible_book_value / shares_outstanding_diluted)
    • Enterprise Value
      market_cap - net_cash
    Source documents
    • Beyond Air, Inc. company facts · 2026-07-10
    • Beyond Air, Inc. 10-K 2026-06-26 · 2026-07-10
    • Beyond Air, Inc. 10-Q 2026-02-13 · 2026-07-10
    • Beyond Air, Inc. 10-Q 2025-11-10 · 2026-07-10
    • Beyond Air, Inc. 10-Q 2025-08-12 · 2026-07-10
    • 8-K (sec_8k_material) on XAIR · 2026-07-10

    Ownership & reference

    Top holders

    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$0M
    • BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$0M
    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$0M
    • JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$0M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M

    Insider activity

    Net buying2 buys · 0 sellsnet $225K2 insiders · last 365d
    • MOORHEAD DANIEL JChief Financial Officer · Common StockBought 4 340 @ $5,76$25K · 2026-07-29
    • Goodman Robert ScottDirector, Chief Executive Officer · Common StockBought 34 722 @ $5,76$200K · 2026-07-29

    Short positioning

    21.4Kshares short-93.5% vs prior
    1days to cover
    61.1%short of daily vol
    1.4Kfails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    XAIRCanonical
    Nasdaq · USD

    Intel & risk

    PredictorM&A prob5 %Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskMedium
    Liquidity riskHigh
    Filings reference going-concern or substantial-doubt language.
    Source documents mention dilution or offering risk.

    Evidence & claims

    From filings & derived data
    • Gross profit (annual): USD 252KUnknown
    • R&D expense (annual): USD 10.24MUnknown
    • EPS (diluted) (annual): USD-PER-SHARES -4Unknown
    • Operating cash flow (annual): USD -18.14MUnknown
    • Net income (annual): USD -33.25MUnknown
    • Pre-tax income (annual): USD -34.33MUnknown
    • Cost of revenue (annual): USD 7.43MUnknown
    • Operating income (annual): USD -29.04MUnknown
    • Revenue (annual): USD 7.68MUnknown
    • Total operating expenses (annual): USD 29.3MUnknown
    • EPS (basic) (annual): USD-PER-SHARES -4Unknown
    • Capex (annual): USD 1.02MUnknown
    • Current liabilities (annual): USD 4.99MUnknown
    • Total liabilities (annual): USD 28.49MUnknown
    • Shares outstanding (annual): 8.4MUnknown
    • Current assets (annual): USD 25.56MUnknown
    • Shareholders' equity (annual): USD 8.11MUnknown
    • Cash & equivalents (annual): USD 6.64MUnknown
    • Total assets (annual): USD 36.77MUnknown
    • Revenue (annual): USD 3.71MUnknown
    • Cost of revenue (annual): USD 5.37MUnknown
    • Gross profit (annual): USD -1.66MUnknown
    • Operating income (annual): USD -44.54MUnknown
    • Capex (annual): USD 5.88MUnknown
    Showing 24 of 39 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ2 2026 earnings (expected) estimated date
    2026-07-29INSIDERMOORHEAD DANIEL J bought 4.3k sh — Chief Financial Officer ~$25k
    2026-07-29INSIDERGoodman Robert Scott bought 34.7k sh — Director, Chief Executive Officer ~$200k
    2026-07-29INSIDERMOORHEAD DANIEL J acquired 4.3k sh Series B Warrant — Chief Financial Officer
    2026-07-29INSIDERGoodman Robert Scott acquired 34.7k sh Series B Warrants — Director, Chief Executive Officer
    2026-07-13EVENT1-for-20 reverse stock split
    2026-07-10 04:37 UTCFILINGMaterial 8-K
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: ma_probability (180d)
    2026-06-28 03:14 UTCHOLDERInstitutional holding changed
    2026-06-28 03:14 UTCHOLDER1 institutional position change flagged
    2026-06-26 00:00 UTCTRANSCRIPTEarnings call — Q2 2026
    2026-06-26 00:00 UTCEARNINGSUpcomingEarnings scheduled →
    2026-06-26EVENTQ2 2026 earnings (expected) estimated date
    2026-06-01FILING8-K filing →
    2026-05-05FILINGDEF 14A filing →
    2026-04-15FILING8-K filing →
    2026-04-10FILING8-K filing →
    2026-04-01FILING8-K filing →
    2026-03-31EARNINGSAnnual results — FY 2026 Revenue USD 7.7M · Net USD -33.2M
    2026-02-13FILING8-K filing →
    2026-02-13FILING10-Q filing →
    2026-02-10FILING424B3 filing →
    2026-02-02FILING8-K filing →
    2026-01-20FILING8-K filing →
    2026-01-15FILING8-K filing →
    2026-01-05 00:00 UTCINSIDER1 insider transaction — 2026-01 1 derivative
    2026-01-05INSIDERMOORHEAD DANIEL J acquired 70.0k sh Stock Option (right to buy) — Chief Financial Officer
    2025-12-31EARNINGSQuarterly results — Q3 2025 Revenue USD 5.8M · Net USD -23.0M
    2025-12-30FILING8-K filing →
    2025-11-04 00:00 UTCINSIDER93 insider transactions — 2025-11 93 derivative
    2025-11-04INSIDERCarey Robert acquired 10.0k sh Stock Options (Right to buy) — Director
    2025-11-04INSIDERCarey Robert disposed of 10.0k sh Stock Options (Right to buy) — Director
    2025-11-04INSIDERCarey Robert acquired 50 sh Stock Options (Right to buy) — Director
    2025-11-04INSIDERCarey Robert disposed of 50 sh Stock Options (Right to buy) — Director
    2025-11-04INSIDERLee Yoori acquired 3.8k sh Stock Options (Right to buy) — Director
    2025-11-04INSIDERLee Yoori disposed of 3.8k sh Stock Options (Right to buy) — Director
    2025-11-04INSIDERLee Yoori acquired 750 sh Stock Options (Right to buy) — Director
    2025-11-04INSIDERLee Yoori disposed of 750 sh Stock Options (Right to buy) — Director
    2025-11-04INSIDERLee Yoori acquired 1.2k sh Stock Options (Right to buy) — Director
    2025-11-04INSIDERLee Yoori disposed of 1.2k sh Stock Options (Right to buy) — Director
    Showing the 40 most recent of 60 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data Premium coverage